Search

Displaying results 1441 - 1450 of 10000 in total
  1. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. … As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

  2. Drug

    Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14389
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze
  3. Drug

    Poliovirus type 1 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10795
    ApprovedInvestigational

    Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: VeroPol Injektionslösung in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
  4. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: VeroPol Injektionslösung in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
  5. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    Until the last review in 2015, this drug is still available in the market.[L1113] … [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Xanthinol

    go.drugbank.com/drugs/DB09092
    ApprovedWithdrawn

    [L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy … [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing.

  7. Target

    Succinate dehydrogenase cytochrome b560 subunit, mitochondrial

    go.drugbank.com/bio_entities/BE0002257
    TargetEnzymeHumans

    Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to

    Synonyms: Succinate dehydrogenase complex subunit C
  8. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) [A256778] and an agonist at the parathyroid hormone type 1 (PTH1) receptor. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.

  9. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.

  10. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14404
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze